A5088518998- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Urinary Bladder and Prostate Research
- Urinary and Genital Oncology Studies
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Urological Disorders and Treatments
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Pelvic floor disorders treatments
- Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Statistical Methods in Clinical Trials
- Renal cell carcinoma treatment
Carolina Urologic Research Center
2016-2025
Peter MacCallum Cancer Centre
2024
Fred Hutch Cancer Center
2023
University of Washington
2023
Genesis HealthCare
2022
Institute of Oncology Research
2022
John Wiley & Sons (United States)
2018-2020
Memorial Sloan Kettering Cancer Center
1991-2020
National Cancer Centre Singapore
2020
Beneficência Portuguesa de São Paulo
2020
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk death among men with metastatic castration-resistant prostate cancer.
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival men with castration-resistant prostate cancer after chemotherapy.In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 chemotherapy according Eastern Cooperative Oncology Group performance-status score and pain intensity. randomly assigned them, a 2:1 ratio, receive...
Multiple loss-of-function alterations in genes that are involved DNA repair, including homologous recombination associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition patients prostate and other cancers.
Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients metastatic, cancer, would delay metastasis in men PSA level.
Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy safety of enzalutamide hormone-sensitive cancer (mHSPC).ARCHES (ClinicalTrials.gov identifier: NCT02677896) is multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume...
Darolutamide is a structurally unique androgen-receptor antagonist that under development for the treatment of prostate cancer. We evaluated efficacy darolutamide delaying metastasis and death in men with nonmetastatic, castration-resistant
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease progressed during previous treatment a next-generation hormonal agent. The results final analysis overall have not yet been reported. In an open-label, phase 3 trial, we randomly...
OBJECTIVE To evaluate the efficacy and safety of degarelix, a new gonadotrophin‐releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving maintaining testosterone suppression in 1‐year phase III trial involving patients with prostate cancer. PATIENTS AND METHODS In all, 610 adenocarcinoma (any stage; median age 72 years; 3.93 ng/mL, prostate‐specific antigen, PSA, level 19.0 ng/mL) were randomized received study treatment. Androgen‐deprivation therapy was indicated...
Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall have not yet been reported. In this double-blind, phase 3 trial, with (defined on basis conventional imaging a PSA doubling time ≤10 months) were continuing to receive therapy...
Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation prostate cancer despite initial testosterone surge and delay in therapeutic effect. The efficacy safety of relugolix, an oral gonadotropin-releasing antagonist, as compared with those leuprolide not known.In this phase 3 trial, we randomly assigned patients advanced cancer, a 2:1 ratio, to receive relugolix (120 mg orally once daily) or (injections every...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for ten most important areas of controversy in advanced prostate cancer (APC) management. successful registration several drugs castration-resistant recent studies chemo-hormonal therapy men with castration-naïve have led to considerable uncertainty as best treatment choices, sequence options appropriate patient selection. Management recommendations based on...
Darolutamide is a structurally distinct androgen-receptor inhibitor that approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In planned primary analysis phase 3 trial, median metastasis-free survival was significantly longer with darolutamide (40.4 months) than placebo (18.4 months). The data overall were immature at time analysis.
BACKGROUND: Preclinical studies and results of a phase 2 trial abiraterone olaparib suggest combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor is with next-generation hormonal agent to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted double-blind, 3 versus placebo in patients mCRPC first-line setting. Patients were enrolled regardless homologous recombination repair gene mutation (HRRm) status. HRRm status was...